Hepatorenal syndrome: Current diagnostic and therapeutic concepts

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL.8, 2007, Pages

  Schepke, Michael ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b Heart Center Siegburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VASOCONSTRICTOR AGENT;

BIOLOGICAL MODEL; CLINICAL TRIAL; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; LIVER TRANSPLANTATION; METHODOLOGY; NEPHROLOGY; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HEPATORENAL SYNDROME; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; NEPHROLOGY; PLACEBOS; PROGNOSIS; RESEARCH DESIGN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 42449118563     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm656     Document Type: Conference Paper

References (21)

1. Gines A, Escorsell A, Gines P et al. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology 1993; 105: 229-236 (Pubitemid 23234041)
2. Alessandria C, Ozdogan O, Guevara M et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to transplantation. Hepatology 2005; 41: 1282-1289 (Pubitemid 40770280)
3. Sanyal A, Boyer T, Garcia-Tsao G et al. A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS). Hepatology 2006; 44 [4 Suppl 1]: 694A
4. Fernandez-Seara J, Prieto J, Quiroga J et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989; 97: 1304-1312 (Pubitemid 19258718)
5. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-176 (Pubitemid 26012105)
6. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827 (Pubitemid 37494763)
7. Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T. Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study. Liver Int 2006; 26: 834-839 (Pubitemid 44165251)
8. Biggins SW, Kim WR, Terrault NA et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660 (Pubitemid 43668830)
9. Schepke M, Roth F, Koch L et al. Prognostic impact of renal impairment and sodium imbalance in patients undergoing transjugular intrahepatic portosystemic shunting (TIPS) for the prevention of variceal rebleeding. Digestion 2003; 76: 146-153 (Pubitemid 36829080)
10. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-930 (Pubitemid 34267275)
11. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403-409 (Pubitemid 29362513)
12. Fernandez J, Monteagudo J, Bargallo X et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005; 42: 627-634 (Pubitemid 41233655)
13. Runyon BA. Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39: 841
14. Gines A, Fernandez-Esparrach G, Monescillo A et al. Randomized trial comparing albumin Dextran 70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-1010 (Pubitemid 26327603)
15. Sola-Vera J, Minana J, Ricart E et al. Randomized trial comparing albumine and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-1153 (Pubitemid 36538692)
16. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648 (Pubitemid 32198689)
17. Ruiz R, Kunitake H, Wilkinson AH et al. Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-741 (Pubitemid 44268509)
18. Marik P, Wood K, Starzl T. The course of type 1 hepato-renal syndrome post liver transplantation. Nephrol Dial Transplant 2006; 21: 478-482 (Pubitemid 43160005)
19. Gines P, Torre A, Terra C, Guevara M. Review article: pharmacological treatment of hepatorenal syndrome. Aliment Pharmacol Ther 2004; 20 [Suppl. 3]: 57-62 (Pubitemid 39279042)
20. Brensing KA, Textor J, Perz J et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in nontransplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47: 288-295 (Pubitemid 30489776)
21. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumine, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology 2004; 40: 55-64 (Pubitemid 38868923)